Jean-Paul Kress joins the Sanofi board of directors

Paris, December 19, 2024. The Sanofi Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024. Jean-Paul Kress will retain his position for the remaining period. of Gilles Schnepp’s mandate and his appointment will be subject to ratification at the next Ordinary General Meeting of Sanofi.

Jean-Paul KressMD, served as CEO of MorphoSys from 2019 until its acquisition by Novartis in 2024. He led the company in its mission – More life for people with cancer – and led its transformation into a global biopharmaceutical company developing and commercializing novel cancer drugs. Prior to that, Jean-Paul Kress was CEO of Syntimmune, where he focused the company on late-stage clinical development in autoimmune diseases until the company’s acquisition by Alexion. He also held several leadership positions with other pharmaceutical companies in the United States and Europe. Jean-Paul Kress was Chairman of the Board of Directors of ERYTECH Pharma and member of the Board of Directors of Sarepta Therapeutics. He holds a doctorate in medicine from the Necker-Enfants Malades Faculty of Paris and a Master of Science in molecular and cellular pharmacology from the Ecole Normale Supérieure (Ulm) in Paris.

Frédéric Oudéa
Chairman of the board of directors
“I express my deepest gratitude to Gilles Schnepp for his unfailing dedication within the Board, and in particular his decisive contribution to the evolution of the company’s governance in 2023. The Board is delighted to welcome Jean-Paul Kress as new director. With several years of diverse pharmaceutical leadership experience, spanning large corporations and biotechnology companies, Jean-Paul brings exceptional global expertise to the board. His knowledge will be invaluable in guiding the company’s continued strategic evolution. the biopharmaceutical field.

Concerning the organization of the Board Committees, Patrick Kron will chair the Nominations, Governance and CSR Committee and Jean-Paul Kress will join the Strategic Committee and the Scientific Committee.

About Sanofi

We are an innovative global healthcare company, driven by a single purpose: we pursue the miracles of science to improve people’s lives. Our team, across the globe, is dedicated to transforming the practice of medicine by striving to turn the impossible into the possible. We provide life-changing treatment options and life-saving vaccine protection to millions of people around the world, while placing sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]

Evan Berland | +1 215 432 0234 | [email protected]
Nicolas Obrist | + 33 6 77 21 27 55 | [email protected]

Leo Le Bourhis | + 33 6 75 06 43 81 | [email protected]
Victor Rouault | + 33 6 70 93 71 40 | [email protected]

Timothy Gilbert | +1 516 521 2929 | [email protected]

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | [email protected]
Alizé Kaiserian | + 33 6 47 04 12 11 | [email protected]

Felix Lauscher | +1 908 612 7239 | [email protected]
Keïta Browne | +1 781 249 1766 | [email protected]

Nathalie Pham | + 33 7 85 93 30 17 | [email protected]

Tarik Elgoutni | +1 617 710 3587 | [email protected]
Thibaud Châtelet | + 33 6 80 80 89 90 | [email protected]

• 
  2024_12_19_GPR_Appointment to the board of directors_ENG